Health Care [ 9/12 ] | Biotechnology [ 43/74 ]
NASDAQ | Common Stock
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems.
The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.
VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 25 | -0.98 Increased by +41.67% | -2.28 Increased by +57.02% |
| Aug 12, 25 | -1.14 Increased by +58.70% | -2.28 Increased by +50.00% |
| May 22, 25 | 4.21 Increased by +225.30% | -2.28 Increased by +284.65% |
| Feb 19, 25 | -2.28 Increased by +47.22% | -2.40 Increased by +5.00% |
| Nov 8, 24 | -1.68 Increased by +61.11% | -2.64 Increased by +36.36% |
| Aug 8, 24 | -2.76 Increased by +50.00% | -0.23 Decreased by -1.10 K% |
| May 23, 24 | -3.36 Increased by +67.28% | -0.28 Decreased by -1.10 K% |
| Feb 13, 24 | -4.32 Decreased by -1.07 K% | -0.36 Decreased by -1.10 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 28.00 K Decreased by -6.67% | -2.54 M Increased by +0.16% | Decreased by -9.09 K% Decreased by -6.97% |
| Jun 30, 25 | 37.00 K Decreased by -5.13% | -2.84 M Increased by +14.98% | Decreased by -7.68 K% Increased by +10.39% |
| Mar 31, 25 | 51.00 K Increased by +75.86% | 6.85 M Increased by +325.02% | Increased by +13.44 K% Increased by +227.96% |
| Dec 31, 24 | 24.00 K Increased by +380.00% | -3.45 M Increased by +4.36% | Decreased by -14.36 K% Increased by +80.07% |
| Sep 30, 24 | 30.00 K Increased by +N/A% | -2.55 M Increased by +36.18% | Decreased by -8.50 K% - |
| Jun 30, 24 | 39.00 K Decreased by -48.00% | -3.34 M Increased by +16.98% | Decreased by -8.57 K% Decreased by -59.65% |
| Mar 31, 24 | 29.00 K Decreased by -82.10% | -3.04 M Increased by +59.18% | Decreased by -10.50 K% Decreased by -128.05% |
| Dec 31, 23 | 5.00 K Decreased by -96.18% | -3.60 M Decreased by -10.42% | Decreased by -72.08 K% Decreased by -2.79 K% |